Generating selective inhibitors with high potency and drug-like pharmacokinetic properties has however been challenging (see for examples refs [41], [42]), although a protein kinase CK2 inhibitor, CX-4945, has been tested in clinical trials for the treatment of cancer [43], [44]. The gene discussed is WEE1; the disease is cancer.